These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24011025)

  • 1. Leukemic transformation driven by an ASXL1 mutation after a JAK2V617F-positive primary myelofibrosis: clonal evolution and hierarchy revealed by next-generation sequencing.
    Ferrer-Marín F; Bellosillo B; Martínez-Avilés L; Soler G; Carbonell P; Luengo-Gil G; Caparrós E; Torregrosa JM; Besses C; Vicente V
    J Hematol Oncol; 2013 Sep; 6():68. PubMed ID: 24011025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia.
    Engle EK; Fisher DA; Miller CA; McLellan MD; Fulton RS; Moore DM; Wilson RK; Ley TJ; Oh ST
    Leukemia; 2015 Apr; 29(4):869-76. PubMed ID: 25252869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ASXL1 alteration cooperates with JAK2V617F to accelerate myelofibrosis.
    Guo Y; Zhou Y; Yamatomo S; Yang H; Zhang P; Chen S; Nimer SD; Zhao ZJ; Xu M; Bai J; Yang FC
    Leukemia; 2019 May; 33(5):1287-1291. PubMed ID: 30651633
    [No Abstract]   [Full Text] [Related]  

  • 4. The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis.
    Helbig G; Wieczorkiewicz A; Woźniczka K; Wiśniewska-Piąty K; Rusek A; Kyrcz-Krzemień S
    Med Oncol; 2012 Dec; 29(4):2379-84. PubMed ID: 22383244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid progression of myelofibrosis in polycythemia vera patient carrying SRSF2 c.284C>A p.(Pro95His) and unique ASXL1 splice site c.1720-2A>G variant.
    Kanduła Z; Kroll-Balcerzak R; Lewandowski K
    J Clin Lab Anal; 2022 May; 36(5):e24388. PubMed ID: 35435261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematopoietic clonal dominance, stem cell mutations, and evolutionary pattern of JAK2V617F allele burden in polycythemia vera.
    Angona A; Alvarez-Larrán A; Bellosillo B; Martínez-Avilés L; Camacho L; Fernández-Rodríguez C; Pairet S; Longarón R; Ancochea Á; Senín A; Florensa L; Besses C
    Eur J Haematol; 2015 Mar; 94(3):251-7. PubMed ID: 25082530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possibility of transformation of primary myelofibrosis to ALL without JAK2V617F mutation.
    Jurisic V; Pavlovic S; Colovic N; Colovic M
    Med Oncol; 2013 Mar; 30(1):398. PubMed ID: 23297051
    [No Abstract]   [Full Text] [Related]  

  • 8. ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden.
    Wang YH; Lin CC; Lee SH; Tsai CH; Wu SJ; Hou HA; Huang TC; Kuo YY; Yao M; Chang K; Lin CW; Lin YC; Tien FM; Chou WC; Tang JL; Tien HF
    Blood Cancer J; 2020 Oct; 10(10):99. PubMed ID: 33046688
    [No Abstract]   [Full Text] [Related]  

  • 9. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.
    Beer PA; Delhommeau F; LeCouédic JP; Dawson MA; Chen E; Bareford D; Kusec R; McMullin MF; Harrison CN; Vannucchi AM; Vainchenker W; Green AR
    Blood; 2010 Apr; 115(14):2891-900. PubMed ID: 20008300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ASXL1 and JAK2V617F gene mutation screening in Iranian patients with chronic myeloid leukemia.
    Valikhani A; Poopak B; Ferdowsi S; Azizi Tabesh G; Ghaffari SH; Saraf Kazeruoni E; Rezaei N; Farshchi A; Amirizadeh N
    Asia Pac J Clin Oncol; 2017 Apr; 13(2):e41-e47. PubMed ID: 27640403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of myeloid sarcoma with correlation to JAK2V617F mutation, complicated by myelofibrosis and secondary acute myeloid leukemia.
    Yoshiki Y; Asai T; Ichikawa M; Hangaishi A; Ota S; Imai Y; Takahashi T; Kurokawa M
    Intern Med; 2011; 50(21):2649-52. PubMed ID: 22041374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ASXL1/EZH2 mutations promote clonal expansion of neoplastic HSC and impair erythropoiesis in PMF.
    Triviai I; Zeschke S; Rentel J; Spanakis M; Scherer T; Gabdoulline R; Panagiota V; Thol F; Heuser M; Stocking C; Kröger N
    Leukemia; 2019 Jan; 33(1):99-109. PubMed ID: 29907810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy for post-myelofibrosis acute myeloid leukemia: eradication of the leukemic clone but not the MPN clone.
    Verger E; Rattarittamrong E; Letort G; Raffoux E; Cassinat B; Kiladjian JJ
    Leuk Lymphoma; 2017 Mar; 58(3):749-751. PubMed ID: 27562925
    [No Abstract]   [Full Text] [Related]  

  • 14. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.
    Abdel-Wahab O; Manshouri T; Patel J; Harris K; Yao J; Hedvat C; Heguy A; Bueso-Ramos C; Kantarjian H; Levine RL; Verstovsek S
    Cancer Res; 2010 Jan; 70(2):447-52. PubMed ID: 20068184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F- and MPLW515 L-positive myelofibrosis.
    Schulze S; Stengel R; Jaekel N; Wang SY; Franke GN; Roskos M; Schneider M; Niederwieser D; Al-Ali HK
    Genes Chromosomes Cancer; 2019 Nov; 58(11):747-755. PubMed ID: 31135094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F.
    Tefferi A; Jimma T; Sulai NH; Lasho TL; Finke CM; Knudson RA; McClure RF; Pardanani A
    Leukemia; 2012 Mar; 26(3):475-80. PubMed ID: 21912393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis.
    Pei YQ; Wu Y; Wang F; Cui W
    Ann Hematol; 2016 Sep; 95(9):1391-8. PubMed ID: 27376361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation.
    Nagase R; Inoue D; Pastore A; Fujino T; Hou HA; Yamasaki N; Goyama S; Saika M; Kanai A; Sera Y; Horikawa S; Ota Y; Asada S; Hayashi Y; Kawabata KC; Takeda R; Tien HF; Honda H; Abdel-Wahab O; Kitamura T
    J Exp Med; 2018 Jun; 215(6):1729-1747. PubMed ID: 29643185
    [No Abstract]   [Full Text] [Related]  

  • 20. Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasms.
    Wang X; LeBlanc A; Gruenstein S; Xu M; Mascarenhas J; Panzera B; Wisch N; Parker C; Goldberg JD; Prchal J; Hoffman R; Najfeld V
    Exp Hematol; 2009 Oct; 37(10):1194-200. PubMed ID: 19615425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.